遗传性阿尔法三血病的临床特征 跨学科实践的影响
Dagmar von Bubnoff1, Daniel Koch, Hannah Stocker
1Department of Dermatology, Allergology, and Venereology, University Hospital Schleswig-Holstein, Campus Lübeck, European Competence Network Mastocytosis (ECNM) Excellence Center for Mast Cell Diseases; Department of Hematology and Oncology, University Hospital Schleswig-Holstein (UKSH) and University Cancer Center Schleswig-Holstein (UCCSH), Campus Lübeck.
Deutsches Arzteblatt international
|January 23, 2024
概括
遗传性α-tryptasemia (HAT) 是一种常见的遗传疾病,导致血清酸酶升高. HAT表现出各种症状,包括神经精神和胃肠道问题,对于跨学科诊断至关重要.
科学领域:
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 遗传性α-tryptasemia (HAT) 是一种自体主导的遗传性疾病.
- 它导致基础血清三酶 (BST) 水平升高 (≥8-11.4μg/L).
- 在英国和法国的流行率为5-6%;在德国是未知的.
研究的目的:
- 审查HAT的临床表现和诊断方面的考虑.
- 突出HAT作为一个重要的差异诊断在跨学科的实践.
主要方法:
- 使用PubMed. 的文献评论.
- 对科学会议演讲的分析.
- 包括临床经验和收集的有关流行率和表现的数据.
主要成果:
- 在BST≥8μg/L (64-74%) 的患者中,HAT很常见.
- 相关症状包括神经精神病 (疲劳,抑郁,睡眠/记忆问题),胃肠道 (易刺激性肠道,恶心,反流) 和巨细胞介导 (发,,疹,过敏反应).
- 在全身性巨细胞症 (12-21%) 中,HAT更为普遍,并且与严重的过敏反应有关.
结论:
- 通过病史和BST测量,可以怀疑HAT诊断.
- 分子基因检测证实了诊断.
- 治疗选择包括抗组胺剂,大细胞稳定剂和IgE抗体.
相关概念视频
Human Genetics
570
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
570
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
394
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
394
Factors Affecting Protein-Drug Binding: Patient-Related Factors
59
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
59


![Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)